According to our new market research study on “North America Gastrointestinal Drugs Market to 2027 – Regional Analysis and Forecast – by Drug Class, Route of Administration, Application, and Distribution Channel” the market is expected to reach US$ 31,664.45 million by 2027 from US$ 21,292.53 million in 2019; it is estimated to grow at a CAGR of 5.2% from 2020 to 2027. The report provides trends prevailing in the North America gastrointestinal drugs market and the factors driving the market growth along with those hindering it.
In 2019, the acid neutralizers segment accounted for the highest share of the market. However, the biologics segment is expected to be the fastest-growing during the forecast period. The CAGR of the biologics segment has the highest CAGR in the forecast period. The growth of the segment is attributed to growing product development and increasing product launches in the market.
The growth of the North America Gastrointestinal Drugs market is mainly attributed to rising prevalence of gastrointestinal (GI) diseases, and increase in development of biologics. However, side effects associated with the drugs will restrict the market growth.
Bausch Health; AbbVie Inc; Johnson and Johnson Services, Inc.; LEXICON PHARMACEUTICALS, INC; and Takeda Pharmaceutical Company Limited are among the leading companies operating in the North America Gastrointestinal Drugs market.
The Report Segments North America Gastrointestinal Drugs Market as Follows:
North America Gastrointestinal Drugs Market – By Drug Class
- Acid Neutralizers
- Antidiarrheal and Laxatives
- Anti-Inflammatory Drugs
- Antiemetic and Antinauseants
- Biologics
- Others
North America Gastrointestinal Drugs Market – By Route of Administration
- Oral
- Parenteral
North America Gastrointestinal Drugs Market – By Application
- Inflammatory Ulcerative Colitis
- Crohn's Disease
- Irritable Bowel Syndrome
- Gastroenteritis
- Celiac Disease
- Others
North America Gastrointestinal Drugs Market – By Country
- North America
- US
- Canada
- Mexico